Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

SIMPLE SUMMARY: Although atezolizumab plus bevacizumab combination therapy was approved in September 2020 as the first immune-combined therapy for hepatocellular carcinoma, the efficacy and safety of this therapy are unclear in real-world practice. This study investigated the early antitumor effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Yuwa, Kawaoka, Tomokazu, Kosaka, Masanari, Shirane, Yuki, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Kosaka, Yumi, Uchikawa, Shinsuke, Kodama, Kenichiro, Fujino, Hatsue, Nakahara, Takashi, Ono, Atsushi, Murakami, Eisuke, Yamauchi, Masami, Okamoto, Wataru, Takahashi, Shoichi, Imamura, Michio, Chayama, Kazuaki, Aikata, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394131/
https://www.ncbi.nlm.nih.gov/pubmed/34439111
http://dx.doi.org/10.3390/cancers13163958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394131/
https://www.ncbi.nlm.nih.gov/pubmed/34439111
http://dx.doi.org/10.3390/cancers13163958

Ejemplares similares